



## Novel aspects of Sjögren's syndrome in 2012

Tincani *et al.*



REVIEW

Open Access

# Novel aspects of Sjögren's syndrome in 2012

Angela Tincani<sup>1,2\*</sup>, Laura Andreoli<sup>2</sup>, Ilaria Cavazzana<sup>1</sup>, Andrea Doria<sup>3</sup>, Marta Favero<sup>3</sup>, Maria-Giulia Fenini<sup>4</sup>, Franco Franceschini<sup>1</sup>, Andrea Lojaco<sup>5</sup>, Giuseppe Nascimbeni<sup>6</sup>, Amerigo Santoro<sup>7</sup>, Francesco Semeraro<sup>6</sup>, Paola Toniati<sup>1</sup> and Yehuda Shoenfeld<sup>8</sup>

## Abstract

Sjögren's syndrome (SS) is a systemic progressive autoimmune disease characterized by a complex pathogenesis requiring a predisposing genetic background and involving immune cell activation and autoantibody production. The immune response is directed to the exocrine glands, causing the typical 'sicca syndrome', but major organ involvement is also often seen. The etiology of the disease is unknown. Infections could play a pivotal role: compared to normal subjects, patients with SS displayed higher titers of anti-Epstein-Barr virus (EBV) early antigens, but lower titers of other infectious agent antibodies such as rubella and cytomegalovirus (CMV) suggest that some infections may have a protective role against the development of autoimmune disease. Recent findings seem to show that low vitamin D levels in patients with SS could be associated with severe complications such as lymphoma and peripheral neuropathy. This could open new insights into the disease etiology. The current treatments for SS range from symptomatic therapies to systemic immunosuppressive drugs, especially B cell-targeted drugs in cases of organ involvement. Vitamin D supplementation may be an additional tool for optimization of SS treatment.

**Keywords:** Anti-B cell therapies, Autoantibodies, Autoimmune diseases, Chronic sialoadenitis, Dry eye syndrome, Lymphoma, Peripheral neuropathy, Sicca syndrome, Sjögren's syndrome, Vitamin D

## Introduction

Sjögren syndrome (SS) is a chronic autoimmune inflammatory disease that primarily involves the exocrine glands, resulting in their functional impairment. The syndrome can present either alone (primary Sjögren's syndrome (pSS)) or in the context of an underlying connective tissue disease, most commonly rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) (secondary Sjögren's syndrome (sSS)) [1].

SS is the second most common autoimmune rheumatic disease, with an estimated prevalence ranging from 0.1 to 4.8% in different studies. It mainly affects middle-aged women, with a female to male ratio reaching 9:1 [2].

Although the etiology of SS remains unknown, susceptibility to the disease can be ascribed to the interplay

between genetic, environmental and hormonal factors. The chronic immune system stimulation is thought to play a central role in the pathogenesis of the disorder, as illustrated by several indices of immunological hyperactivity, including various autoantibodies, in particular anti-Ro/SS-A (anti-Ro) and anti-La/SS-B (anti-La) [1].

A genetic predisposition to SS has been suggested [3]. Familial clustering of different autoimmune diseases and coassociation of multiple autoimmune diseases in individuals have both frequently been reported. It is common for a SS patient to have relatives with other autoimmune diseases (30%) [1]. The polymorphic major histocompatibility complex (MHC) genes are the best documented genetic risk factors for the development of autoimmune diseases; with regard to SS, DRB1\*0301-DQB1\*0201-DQA1\*0501 haplotypes are the strongest risk factors for the formation of an anti-Ro/La response and to the development of the disease [4].

Although many human leukocyte antigen (HLA) haplotypes have been found in SS subjects from different ethnic boundaries, the majority of patients with SS carry a common allele, DQA1\*0501, probably involved in

\* Correspondence: tincani@med.unibs.it

<sup>1</sup>Rheumatology and Clinical Immunology Unit, Spedali Civili, Piazzale Spedali Civili 1, 25100 Brescia, Italy

<sup>2</sup>Chair of Rheumatology, Department of Clinical and Experimental Sciences, University of Brescia, Spedali Civili, Piazzale Spedali Civili 1, 25100 Brescia Italy

Full list of author information is available at the end of the article

predisposition to the disease [5]. Regardless, no significant different geographic distribution has been described in pSS to date [6].

In the current review we present the complexity of SS from different points of view, reporting on the current cutting edge of knowledge about this disease. This multidisciplinary approach to SS is the result of a symposium held in Brescia (Italy) in June 2012, involving several specialists who take care of different aspects of the diagnosis, management and therapy of SS.

### Clinical features and classification

SS typically presents as dry eyes (xerophthalmia or keratoconjunctivitis sicca (KCS)) and dry mouth (xerostomia) [7]. KCS usually presents insidiously over a period of several years. Affected patients may describe a 'gritty' or 'sandy' feeling in their eyes [8]. Complications of xerophthalmia include corneal ulceration and infection of the eyelids. Dryness of the mouth may give rise to difficulties in the swallowing of dry foods without fluid, and need for frequent small sips of water, also at night. Loss of the protective and antimicrobial properties of saliva may increase dental caries and predispose patients to oral candidiasis. Parotid swelling and other xeroses, such as dryness of the nose, throat, skin, and vagina, also often occur [8].

Establishing the diagnosis of SS is often difficult. The symptoms are non-specific: sicca symptoms are extremely common, especially in older patients, partly due to age-related atrophy of secreting tissues and partly due to other conditions, especially use of drugs.

No single laboratory test allows for definitive diagnosis of SS. However, a combination of abnormal test results is frequently observed: elevated erythrocyte sedimentation rate (ESR), mild normochromic normocytic anemia, leukopenia and polyclonal hypergammaglobulinemia.

Autoantibodies are present in the majority of SS cases: rheumatoid factor (RF), Anti-nuclear antibodies (ANA) and anti-Ro and anti-La are strongly indicative of SS, although not exclusive [8].

There is no single disease-specific diagnostic criterion for SS. The most widely used classification criteria are those revised in 2002 by a joint effort by research groups in Europe and in the USA (American-European Consensus Group (AECG)) (Table 1) [9,10]. In addition to the subjective symptoms of dry eyes and dry mouth, the following objective signs should be present: ocular signs by Schirmer's I test and/or Rose Bengal score; focal sialadenitis by histopathology; salivary gland involvement by salivary scintigraphy, parotid sialography or unstimulated salivary flow; and autoantibodies of anti-Ro and/or anti-La specificity. The diagnostic role of the histopathology of minor salivary glands has been considered important and is currently considered as a 'gold standard', although a recent meta-analysis has shown that the

diagnostic usefulness has actually only been evaluated in a few studies [11].

Recently, the Sjögren's International Collaborative Clinical Alliance (SICCA) proposed a new expert consensus approach consisting of classification criteria based entirely on objective measures [12]. In particular, not only have ocular and oral symptoms have been deleted, but also the study of salivary gland involvement has been excluded from the criteria (Table 1).

In fact, the evaluation of salivary gland involvement in SS is still a matter of debate. In addition to standard tests for assessment of salivary gland involvement, namely the unstimulated salivary flow test, salivary gland scintigraphy and contrast sialography, other methods have been studied such as magnetic resonance sialography and ultrasonography (US) [14]. It has been suggested that US may provide useful diagnostic information comparable to that of biopsy of the minor salivary glands, but US is less expensive and non-invasive [15,16].

### Differential diagnosis of 'dry eye'

The importance of objective tests for the definition of ocular dryness has been stressed by the 2012 criteria [12]. Therefore, correct evaluation of a 'dry eye' becomes critical in the investigation of patients with a suspected case of SS.

Dry eye syndrome is a common but very complex disorder of the tear film. Over the last few decades substantial progress has been made in understanding the structural elements of the tear film and ocular surface leading ultimately to revised concepts about the way in which the tear film is formed and maintained, and the pathophysiologic events operative in the development of dry eye.

The structure of tear film can be subdivided into an anterior lipid layer, a middle aqueous layer and an innermost mucin layer. Meibomian glands, lacrimal glands, goblet cells and epithelial cells of the ocular surface produce these layers. In the 1980s, for the first time, researchers started to consider that the ocular surface is a functional unit (lacrimal functional unit (LFU)), and its components are represented by the lacrimal gland, corneal epithelium, conjunctival epithelium and goblet cells, tear film and the eyelid border with Meibomian glands [17]. The ocular surface is essential for visual function and is considered as an interface between the external environment and the host. Hydrodynamic factors, such as eyelid blinking and closure, are essential to maintain ocular surface functionality. In 1995, the Dry Eye Study Group [18] described 'dry eye syndrome' as a tear film pathology that occurs due to either decreased tear production or increased evaporation. It causes damage to the interpalpebral ocular surface and is associated with a variety of symptoms reflecting ocular discomfort

**Table 1 Comparisons between the 2002 and 2012 criteria for Sjögren's syndrome (SS)**

2002 criteria from the American-European Consensus Group (AECG) (Vitali <i>et al.</i> [9])	2012 criteria from the Sjögren's International Collaborative Clinical Alliance (SICCA) (Shiboski <i>et al.</i> [12])
(I) Ocular symptoms (positive response to at least one of three): Daily, persistent, troublesome eyes for more than 3 months Recurrent sensation of sand or gravel in the eyes Use of tear substitutes more than three times per day	(I) Ocular symptoms: Not included
(II) Oral symptoms (positive response to at least one of three): Daily feeling of dry mouth for more than 3 months Recurrently or persistently swollen salivary glands as an adult Frequent drinking of liquids to aid in swallowing food	(II) Oral symptoms: Not included
(III) Ocular signs (positive result for at least one of two tests): Schirmer's test, performed without anesthesia ( $\leq 5$ mm in 5 minutes)  Rose Bengal score or other ocular dye score ( $\leq 4$ according to van Bijsterveld's scoring system)	(III) Ocular signs: Keratoconjunctivitis sicca with ocular staining score $\geq 3$ , according to Whitcher <i>et al.</i> [13] (preferential use of fluorescein staining or lissamine green staining, but break-up time; and unanesthetized Schirmer's test can also be used). It is assumed that individual is not currently using daily eye drops for glaucoma and has not had corneal surgery or cosmetic eyelid surgery in the last 5 years).
(IV) Histopathology in minor salivary gland biopsy: Focal lymphocytic sialadenitis, with focus score $\geq 1$ (a focus is defined as $\geq 50$ lymphocytes per $4 \text{ mm}^2$ of glandular tissue adjacent to normal appearing mucous acini)	(IV) Histopathology in minor salivary gland biopsy: Focal lymphocytic sialadenitis, with a focus score $\geq 1$ (a focus is defined as $\geq 50$ lymphocytes per $4 \text{ mm}^2$ of glandular tissue adjacent to normal appearing mucous acini)
(V) Salivary gland involvement (positive result for at least one of three): Unstimulated whole salivary flow ( $\leq 1.5$ ml/15 minutes) Parotid sialography showing the presence of diffuse sialectasis (punctuate, cavitory or destructive pattern), without evidence of obstruction in the major ducts Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer	(V) Salivary gland involvement: Not included
(VI) Autoantibodies: Presence in the serum of antibodies to Ro (SS-A) or La (SS-B) antigens, or both	(VI) Autoantibodies: Positive serum anti-SS-A/Ro and/or anti-SS-B/La or (positive rheumatoid factor and anti-nuclear antibody (ANA) titer $\geq 1:320$ )
Classification criteria: Primary SS: The presence of any four of the six items, as long as either item IV (histopathology) or item VI (serology) is positive The presence of any three of the four objective criteria (items III, IV, V and VI) Secondary SS: In the presence of another connective tissue disease, the presence of item I or item II, plus any two from items III, IV and V	Classification criteria: At least two of the three items in order to classify a patient as SS
Exclusion criteria: Past head and neck radiation treatment, hepatitis C infection, AIDS, pre-existing lymphoma, sarcoidosis, graft versus host disease, use of anticholinergic drugs (since a time shorter than fourfold the half-life of the drug)	Exclusion criteria: History of head and neck radiation treatment, hepatitis C infection, AIDS, sarcoidosis, amyloidosis, graft versus host disease, IgG4-related disease

(Figure 1). Until recently this was the common definition of 'dry eye syndrome'. However, the international report of the Dry Eye Workshop (DEWS) changed the definition of dry eye in 2007 [19]. According to DEWS, 'dry eye syndrome' is a multifactorial disease of the tears

and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface itself. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. The tear film is a very



**Figure 1** Severe ocular surface damage in a dry eye patient.

important and highly dynamic part of the ocular surface system, which promptly responds to pathological events with modifications of quantity and quality of tear production, an increase in proliferation and migration of epithelial cells and permeability of conjunctival vessels. Another crucial component of the system is the neural network. Sensory receptors monitor conditions of the tears and cells, sending afferent signals to the central nervous system that, in turn, send efferent impulses mainly to the secretory glands and cells, effecting changes in composition and volume to maintain homeostasis and to respond to injury and stress. As stated before, dry eye is a multifactorial disorder of the LFU; it involves several interacting mechanisms. Dysfunction of any component can lead to dry eye disease by causing alterations in the volume, composition, distribution, stability and clearance of the tear film. A key role is played by decreased tear production and epithelial damage along with tear hyperosmolarity and tear film instability. Altogether these events start self-perpetuating and mutually reinforcing complex global mechanisms, ultimately leading to ocular surface inflammation [20]. The latter, regardless of the initiating event, is a key factor perpetuating dry eye.

According to the DEWS report, dry eye disease comprises two major etiopathogenic groups: evaporative dry eye and aqueous tear-deficient dry eye (Figure 2). Hyperevaporative dry eye can be due to intrinsic and extrinsic causes. Among the first group are changes in tear composition, eyelid disorders, incomplete blinking or reduced blinking rate, ocular surface irregularities and drug action. Extrinsic causes include, among others, vitamin A deficiency, topical drug preservatives, contact lens wear and ocular surface disease. Aqueous tear deficient dry eye can be subdivided into SS and non-SS syndrome dry eye groups. The latter group has several primary causes, including the lack of a lacrimal gland (congenital

or acquired), impairment or dysfunction of the lacrimal gland, reflex block and drug action. Non-SS dry eye can also be secondary to a variety of conditions. SS dry eye is associated with autoimmune inflammation in the lacrimal glands [19].

It should be remembered, however, that instances of hyperevaporative and aqueous tear deficient dry eye in most cases are not clinically so well defined and often there is a certain degree of overlap between these two dry eye groups. A hyperevaporative dry eye over time also becomes aqueous tear deficient, and vice versa, making it difficult to precisely classify the condition.


Ophthalmologists should recognize and diagnose dry eye syndrome to prevent or treat ocular surface pathologies. As it may be associated with a variety of causes, it is important to perform a comprehensive evaluation. This should include a complete clinical history, accurate examination of the patient (skin, blinking rate, eye and lid morphology, and so on), a slit-lamp examination and laboratory tests that can help towards a diagnosis of dry eye related to SS. Lacking a single conclusive test to diagnose dry eye syndrome, a lot of different procedures, easy or complicated, cheap or expensive and more or less useful, have been developed in order to help ophthalmologists. The tests of choice to diagnose dry eye include break-up time (BUT), ocular surface staining and Schirmer's test [12]. The reasons for their use lay in their reproducibility, sensitivity and in the fact that all of them are quite easy to perform. Ocular surface dyes used in clinical practice are fluorescein and lissamine green (Figure 3). Rose Bengal was progressively abandoned because of patient discomfort. The lissamine green dye test is very sensitive and stains damaged epithelial cells without causing any discomfort to patients.

Once a diagnosis is confirmed, management of dry eye depends on the cause and severity of the condition. New treatment approaches are designed to modify the underlying disease process. Every associated condition must be treated. Therapy should normalize the tear film, decrease ocular surface inflammation, stimulate epithelial healing, improve neural feedback, decrease lacrimal gland inflammation and improve its function.


In conclusion, therapy should be aimed at protecting the ocular surface, alleviating the signs and symptoms of dry eye and, most importantly, at breaking the vicious cycle leading to chronic inflammation, thus improving the quality of life of patients.

#### **Not only 'sicca syndrome': extraglandular manifestations of SS**

Despite glandular involvement being the major and typical feature of pSS, this autoimmune disease can have several systemic manifestations. In fact, 30% to 70% of patients develop systemic involvement before or after



the diagnosis of pSS [21-24]. In addition, it must be considered that this group of patients more commonly has circulating anti-Ro and anti-La autoantibodies, in comparison with the group of patients with sicca-limited disease [25].



Most extraglandular manifestations, similar to the exocrine gland involvement, can be considered as expression of the so-called 'autoimmune epithelitis' because the primary target of the autoimmune response is the epithelial component [26,27]. Nevertheless, in other clinical manifestations the pathogenesis seems to be completely different as it may involve vasculitis and/or immune complex deposition and complement activation, as is the case in skin vasculitis, glomerulonephritis and peripheral neuropathy.

One of the most frequent symptoms in pSS is represented by fatigue, prominent in approximately 70% of patients. Though the instruments for fatigue assessment are still inadequate or lacking, it seems that the physical and somatic rather than mental aspects of fatigue are more severely and frequently affected in pSS [28]. A moderate correlation between depression and fatigue has also been found. One possible explanation is that fatigue and depression share common underlying biological mechanisms.

Respiratory manifestations are frequently detected but they are clinically significant in only 10% of patients [29]. The more common clinical symptoms are represented by

nasal crusting, epistaxis, recurrent sinusitis, dry cough and dyspnea. They are caused by dry nose, dry trachea, small airway obstruction and/or interstitial lung disease (ILD). Non-specific interstitial pneumonia (NSIP) seems to be the most frequent histological pattern of ILD but lymphocytic IP (LIP) and usual IP (UIP) are also present.

The kidneys are often involved in pSS. The major clinicopathological entity is interstitial nephritis (IN), which appears early or even may precede the onset of sicca symptoms [30]. Distal renal acidosis (both type I and II) is the most frequent clinical presentation. Aside from IN, glomerulonephritis (GMN) is more rarely detected in patients with pSS and is strongly associated with low C4 levels and mixed cryoglobulinemia. However, IN is frequently subclinical and overt clinical renal disease is detectable in approximately 5% of patients with pSS, in which IN and GMN are almost equally distributed.

With regard to skin involvement, nearly half of all patients with pSS may present cutaneous manifestations consisting of skin xerosis, angular cheilitis, erythema anulare, chilblain lupus and skin vasculitis that includes flat or palpable purpura and urticarial vasculitis [31].

Arthralgias are commonly reported in patients with pSS while typical non-erosive arthritis is less frequent [32]. Likewise, myalgias are frequent while myositis is rarely diagnosed in pSS.

Gastrointestinal manifestations include nausea, dysphagia or epigastric pains that are frequently due to dryness of the pharynx and esophagus or to esophageal dysmotility and gastritis. The typical histological pattern is chronic atrophic gastritis with lymphoid infiltration. Hyperamylasemia is rather frequent, though very rarely it is an expression of acute or chronic pancreatitis. Abnormal liver tests are not uncommon but autoimmune hepatitis is diagnosed in 1.7% to 4% of patients with pSS, while autoimmune cholangitis (with histological changes similar to stage I primary biliary cirrhosis) develops mainly within the 5% to 10% of patients with antimitochondrial antibodies [33].

Approximately 20% of patients with pSS develop autoimmune thyroiditis (primarily Hashimoto thyroiditis and to a lesser extent, Graves' disease) and more than 50% of them have subclinical hypothyroidism. Autoantibodies against thyroid peroxidase (anti-TPO) and thyroglobulin (anti-TG) can be used as primary indicators of patients who are prone to developing thyroid disease in the future [34].

The prevalence of neurological manifestations in pSS varies between 2% to 60% with pure or predominantly sensory polyneuropathies being the most common manifestations (for example, sensory ataxic or small fiber sensory painful neuropathy) [21,35]. Sensorimotor polyneuropathy and polyradiculopathy, mononeuritis multiplex, autonomic neuropathy (for example, Adie's pupils and orthostatic

hypotension), trigeminal and other cranial neuropathies are other manifestations of the involvement of peripheral nervous system (PNS) in pSS. Central nervous system involvement is much less common than PNS involvement, with multiple sclerosis-like changes, seizures, transverse myelitis, aseptic meningitis, optic neuritis, diffuse encephalopathy and dementia as reported manifestations [36].

### **Pathogenesis, histopathology and progression to lymphoma**


The pathological hallmark of SS is a chronic inflammatory infiltrate in the exocrine glands, mainly constituted by activated T and B cells [37,38]. The immune-mediated damage appears in the apoptosis of glandular epithelial cells [39] and seems to be mediated by several proinflammatory T helper 1-type cytokines [40]. The epithelial cells of salivary glands from patients with SS also display alterations in cell adhesion and shape [41]. The immune dysregulation seems to be orchestrated by genetic factors, including certain HLA phenotypes and polymorphisms in genes encoding cytokines or factors implicated in cytokine signaling, by the environment (such as viruses) and by the hormonal milieu [42].

The histopathological picture of SS is the chronic periductal sialoadenitis [43]. In the early stages of disease, focal aggregates of lymphocytes appear in the glandular lobules. Initially, the lymphocytes infiltrate the space around small interlobular-intralobular ducts, and subsequently they determine the atrophic involution of the acina. The lymphocyte infiltrate then spreads from the periductal position to the parenchyma, with the final result of a diffuse infiltration of lymphocytes and loss of tissue architecture. In addition, the lymphocytes initiate the damage to the ducts with the formation of epimyoeplithelial lesions. As a result, hyaline material, similar to a basal membrane, is present in the lumen of the ducts. Of note, some morphological alterations described in SS ('epimyoeplithelial sialoadenitis') can also be found in the absence of overt disease (no clinical and serological features of SS). Such a histopathological picture can be defined as a 'benign lymphoepithelial lesion'.

According to the international guidelines [9,12], the histological criteria for the definition of SS are both qualitative and quantitative: the 'focus' must be composed of at least 50 lymphocytes infiltrating the periductal area; 1 focus must be detected in a tissue area of at least 4 mm<sup>2</sup> (see Figure 4).



The main complication of SS is hematological neoplasia. Compared to healthy individuals, patients with SS have a 10 to 50 times higher risk of lymphoma and, according to a large case series, 2% to 9% of patients with SS develop lymphoma [7].

The parotid gland is affected in the majority of cases and the most frequent type of non-Hodgkin's (NH)



lymphoma is the marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). Such lymphomas can also be found in other organs (stomach, lungs and kidney). Other types of lymphoma are rare in SS: Hodgkin's lymphoma, B cell NH lymphoma with diffuse giant cells and centrofollicular histotypes and T cell NH lymphoma [44].

Despite the inflammatory infiltrate in the salivary glands being mostly made up of T cells, the development of lymphoma involves the B cells. The lymphoma cells in the marginal zone NH type are medium-sized cells with a cleaved nucleus and large cytoplasm (Figure 5) and with a positive CD20 reaction (Figure 6). Such cells cluster in the epimyoeplithelial islets. Initially, there might be several different clones of B cells, but over time



a single clone can progressively expand and invade the glandular parenchyma with the formation of a lymphoma.

Risk factors for the development of lymphoma have been identified in patients with SS and include the presence of palpable purpura, low C4 and mixed monoclonal cryoglobulinemia. Patients displaying these risk factors should be monitored closely [44].

#### Serological profile

SS is an autoimmune disease characterized by a strong polyclonal B cell activation and different circulating autoantibodies, classically represented by anti-nuclear antibodies, anti-Ro, anti-La, rheumatoid factor and, more rarely, anti-centromere, anti-Ki/SL, anti-Ku or anti-p80 coilin.

Other autoantibodies have been described in SS, probably involved in the pathogenesis of different aspect of the disease, such as anti- $\alpha$  fodrin [45], anti-carbonic anhydrase, and anti-muscarinic receptor antibodies [46].

Anti-Ro and anti-La antibodies are considered the classical hallmark of SS, detected in about 60% and 40% of SS, respectively, and included in both the AECG and SICCA classification criteria [9,12]. Anti-Ro and anti-La antibodies define a disease with a higher rate of extraglandular manifestations and more active immunological status, when compared with 'seronegative' SS cases (without anti-Ro or anti-La antibodies). Anti-Ro/La-positive patients with SS can show severe hypergammaglobulinemia, cryoglobulins and a high risk of developing lymphoma [47].

Circulating levels of anti-Ro/La do not correlate with disease activity; regardless, the IgA anti-Ro titer seems to be associated with the rate of lymphocyte glandular infiltration. In addition, the expression of La and 60 kDa Ro antigens in ductal glandular cells could represent a



trigger for inducing and maintaining a local inflammation and tissue-specific immune response. Moreover, a strong correlation was found between circulating autoantibodies and Ro/La producing cells in salivary glands [48]. Anti-Ro and anti-La autoantibodies from SS sera, but not healthy IgG, can activate caspase 3 and determine apoptosis in human salivary gland cells, *in vitro* [49]. In addition, anti-Ro/SS-A antibodies stimulate the production of proinflammatory cytokines interleukin (IL)-6 and IL-8 by human healthy salivary gland epithelial cells [50]. Therefore, these autoantibodies seem to have a pathogenic role for the impairment of the secretory function in the salivary glands.

Anti-Ro antibodies recognize a macromolecular complex, constituted by 60 kDa and 52 kDa Ro proteins and short cytoplasmic RNA molecules. The 60 kDa and 52 kDa Ro antigens are encoded by different genes and are completely different in amino-acid sequence, epitopes and biological role within the cell. The 60 kDa Ro is directly bound to RNA of the Ro complex and seems to have a role in DNA replication. By contrast, 52 kDa Ro does not contain an RNA-binding sequence but could be considered part of the 'Ro protein' through the link with 60 kDa Ro: it seems to have a role in ubiquitination and modulation of innate immune system through regulation of proinflammatory cytokines and interferon related factors. Anti-Ro antibodies recognize isolated 60 kDa Ro (which contains only conformational epitopes) or 60 kDa Ro associated with 52 kDa Ro (which has only linear epitopes). Isolated anti-52 kDa Ro antibodies can be found in SS, but they can also be frequently detected in other autoimmune disorders [51,52]. Interest has been raised for anti-52 kDa Ro, as there are new insights on the mechanisms of intracellular immunity mediated by these autoantibodies when they penetrate into cells [53].

Almost every assay can accurately detect anti-La antibodies. By contrast, the correct assays for anti-Ro antibodies should use raw or conformational antigens in order to detect autoantigens with the best sensitivity and specificity. Counterimmunoelectrophoresis, using raw spleen extracts, shows a similar performance level to the 'gold standard' immunoprecipitation assay. Western blotting tests, ELISAs and multiplex microbead immunoassays show variable results depending on antigen purification, synthesis and maintenance of conformational epitopes of Ro peptides [54].

Other autoantibodies can be detected in SS, as associated or substitutes of anti-Ro antibodies [46]. Anti-centromere antibodies (ACA), usually found in limited systemic sclerosis (SSc), are detected in 5% to 10% of SS cases as an alternative to anti-Ro/La antibodies. ACA-positive SS shows SSc features, such as Raynaud's phenomenon, puffy hands, dysphagia and teleangiectasia, but has a lower rate of pulmonary involvement compared

to ACA + SSc. These patients show sicca symptoms not due to glandular fibrosis, as observed in SSc, but due to a high rate of lymphocyte infiltration as well as anti-Ro/La-positive SS. These data suggest that ACA-positive SS could be considered an overlap SS/SSc disease [55].

Anti-Ki/SL, anti-Ku and anti-p80 coilin antibodies are more rarely found in SS. Anti-Ki/SL antibodies, originally found in SLE with sicca, have been described in primary SS in association with anti-Ro or as isolated markers [56]. Anti-p80 coilin has been detected in SS or SSc, especially when associated with primary biliary cirrhosis [57]. Moreover, anti-Ku antibodies are usually considered markers of overlap SSc-myositis or SSc/SLE syndrome [58]. They have been detected in SS with features of SSc, cutaneous lupus and/or myositis.

In summary, most patients with SS show a mild disease with a simple autoantibody profile. Regardless, anti-Ro and La antibodies likely play a pathogenic role in inducing local inflammation and damage and are serological markers of systemic complications. Other autoantibodies, such as ACA and anti-Ku, may define a more complex disease with overlap features and different prognosis.

#### Association of SS with other autoimmune diseases

SS may occur in isolation, often referred to as primary SS, or in conjunction with another connective tissue disease, most commonly RA or SLE [59]. This association is termed secondary SS, according to the AECG, even if SS was diagnosed as secondary disease many years before the primary disease [9].

SS has been described in association with a large variety of both organ-specific and systemic autoimmune diseases. In a series of 114 patients with pSS [60], a range of 13 associated autoimmune diseases was detected. In all, 38 patients (33%) were diagnosed as having 1 additional autoimmune disease, 7 (6%) had 2, and 2 (2%) had 3. The most common autoimmune disorder was hypothyroidism (14%). Similarly, a more recent cohort of 410 patients with SS [61] showed the presence of polyautoimmunity in 134 (32.6%), with thyroid disease being the most common (21.5%). The prevalence of systemic diseases such as RA and SLE was around 8%. As the presence of a concomitant autoimmune disease involves nearly one-third of patients with SS, a common pathogenic background may be advocated and the search for polyautoimmunity is warranted in every SS patient.

The relationship between SS and SLE has been recently addressed in a meta-analysis [62]. In a total of 2489 SLE patients, the estimated prevalence of SS was 17.8%. The clinical features of SLE-SS patients were found to be: (i) older age, (ii) increased frequency of oral ulcers and arthritis and (iii) proteinuria and CNS involvement, though these tended to be less frequent.

With regard to autoantibodies, anti-double-stranded DNA antibodies were equally present in both groups, while anti-Ro and anti-La were more frequent, and anti-Sm and anti-cardiolipin antibodies were less prevalent in SLE-SS than SLE alone. Overall, the combined disease SLE-SS seems to be characterized by less organ involvement, a more specific autoantibody profile and a favorable clinical outcome.

The evolution towards SLE in patients with pSS has also been addressed. In a cohort of 100 patients with pSS, 15% of them could be classified as having SLE after a follow-up period of 10 years. Patients who developed SLE had a lower age, lower C3 concentration, higher level of IgG, and the presence of anti-La at the time of diagnosis of pSS [63]. In a larger cohort of 445 patients with pSS, the development of SLE was observed in only 1.3% of the patients, after a mean period of 77 months [64].

RA is frequently associated with both sicca symptoms and true sSS. In a Spanish cohort of RA patients, a cumulative prevalence of sSS was described in 17% of the patients at a disease duration of 10 years [65]. In a cohort in Austria the reported prevalence of sSS was 22% [66].

In a Greek cohort, RA patients with high titers of RF were reported to be more likely to have sSS [67]. In Finland, a doubled standardized incidence ratio for NH lymphoma in RA patients with sSS when compared with RA patients without SS was described [68].

Sicca syndrome is also common among patients with SSc due to fibrotic changes of the salivary glands. In original cohorts of SSc patients the prevalence of sSS was reported to be 17% and 29% [69,70].

In 2 more recent studies involving 133 patients with SSc and sicca syndrome (14% classified as sSS) [71] and 27 patients with SSc + sSS compared with 202 SSc patients without sSS [72], it was found that SS associated with SSc was more often complicated by peripheral neuropathy and additional autoimmune disease or autoantibodies, not typical for either pSS or SSc. It was suggested that SS may be protective against systemic sclerosis-associated pulmonary fibrosis. Limited SSc was predominantly associated with SS in these studies (81% and 95%, respectively).

There have been no studies to date of patients with mixed connective tissue disease (MCTD) that report the prevalence of SS. The development of MCTD in pSS has not been described so far [60,64]. The prevalence of anti-ribonucleoprotein autoantibodies (anti-RNP) in the absence of coexisting MCTD has been reported in 4% of patients with pSS [55].

#### **Novel aspects of SS: the role of infections and vitamin D** **Infections and SS**

The etiology of autoimmune diseases (AID) is multifactorial where genetic, immunologic, hormonal and environmental

factors play in concert in their induction. The final step determining the date of emergence of an AID is most probably an environmental trigger, which is generally of infectious origin [73]. In the interplay between infectious agents and autoimmunity it was found that the same infectious agent (that is, Epstein-Barr Virus (EBV)) may be involved in inducing many autoimmune diseases, while the same autoimmune disease may be caused by various agents (that is, EBV, cytomegalovirus (CMV), *Helicobacter pylori*, and so on) [74].

Recently, several multicenter studies analyzed a large number of sera samples (>2,500) from patients with AID such as SS, SLE, antiphospholipid syndrome (APS), RA, vasculitides, and others for the presence of a profile of anti-infectious agents antibodies including EBV, CMV, *H. pylori*, rubella, treponema, Herpes virus and toxoplasmosis. In several diseases a higher prevalence and titers of anti-infectious antibodies were found compared with healthy controls matched for sex, age and ethnicity [75-80]. For instance, in patients with SS the prevalence and titers of antibodies against EBV-early antigen were significantly higher than in their control group ( $P = 0.0003$ ).

Interestingly, in some diseases lower titers of anti-infectious agents were found, such as the lower prevalence and titers of rubella and CMV antibodies (IgM) detected in patients with SS compared to controls ( $P < 0.02$ ). This may allude indirectly to the notion that some infectious agents may have a protective rather than a pathogenic role for a specific autoimmune disease.

Furthermore, a certain infectious agent may determine why an individual with the 'proper' genetic background will develop one AID rather than others, as well as its clinical manifestations and severity.

#### **Low levels of vitamin D are associated with neuropathy and lymphoma among patients with SS**

The morbidity of SS is mainly determined by extraglandular disease and increased prevalence of lymphoma. Environmental and hormonal factors, such as vitamin D, may play a role in the pathogenic process and disease expression.

The levels of vitamin D and their association with manifestations of SS were studied in a large international multicenter cohort [81]. Vitamin D levels were determined in 176 patients with pSS and 163 matched healthy volunteers utilizing LIAISON chemiluminescent immunoassays (DiaSorin, Saluggia, Italy). Mean vitamin D levels were comparable between patients with SS and controls:  $21.2 \pm 9.4$  ng/ml and  $22.4 \pm 10$  ng/ml, respectively. Peripheral neuropathy was diagnosed in 23% of patients with SS and associated with lower vitamin D levels ( $18.6 \pm 5.5$  ng/ml vs  $22.6 \pm 8$  ng/ml ( $P = 0.04$ )). Lymphoma was diagnosed in 4.3% of patients with SS, who had lower levels of vitamin D,  $13.2 \pm 6.25$  ng/ml,

compared to patients with SS without lymphoma ( $22 \pm 8$  ng/ml;  $P = 0.03$ ). Other clinical and serological manifestations did not correlate with vitamin D status.

This study reported for the first time the presence of low vitamin D levels in patients with pSS with peripheral neuropathy. Overall, it seems that vitamin D deficiency may be a component in the pathogenesis of neuropathy in pSS, and may be used for monitoring and treatment of this condition [82-87].

Patients with pSS are at increased risk for NHL lymphoma compared to healthy populations [44]. While the relationship between vitamin D and the risk for lymphoma in pSS has not been reported previously, there is some evidence from case-control studies that low dietary intake of vitamin D is associated with an increased risk for NHL in the normal population [88,89]. Vitamin D and its metabolites have been shown to have an antiproliferative effect on lymphoma cell lines and to attenuate their vitamin D receptor (VDR) expression [90].

Thus, low vitamin D levels may join low complements components and the presence of cryoglobulins in predicting eventual development of lymphoma in patients with SS.

Given the associations between hypovitaminosis D and severe complications of SS, it can be proposed that vitamin D supplementation should be given to every patient with SS.

#### **Sjögren's syndrome: a female disease**

Interestingly, it has also recently been claimed that vitamin D may be linked with a severe complication that may affect pregnant women with anti-Ro and anti-La: congenital heart block (CHB). CHB is the result of the passive transfer of maternal autoantibodies to the fetus in the presence of genetic predisposing factors that allow antibody-mediated cardiac damage [91].

A recent study conducted in Sweden found out that a greater proportion of children with CHB were born during the summer [92]. This means that the gestational period of enhanced CHB susceptibility (18 to 24 weeks of gestation) occurred during January to March, which is the time of the year when vitamin D levels were at their lowest. The authors concluded that the seasonal timing of the pregnancy may be critical to the onset of CHB and that vitamin D could be a possible mediator of such seasonal variation.

Aside from the severe complication of CHB, the presence of anti-Ro and anti-La antibodies does not seem to affect the gestational outcome as compared with pregnant women with autoimmune diseases negative for anti-Ro and anti-La. In a large case-control study, no difference was found in terms of pregnancy loss, intrauterine fetal deaths, preterm delivery and small-for-gestational-age infants [93]. However, when compared to

age-matched healthy pregnant women, mothers with SS seem to give birth to offspring of lower birthweight and a normal delivery is less common.

Patients with SS can also suffer from gynecological problems more often than healthy women. Vaginal dryness and dyspareunia affect more than half of patients, with a significant difference with age-matched normal controls [94-96]. In addition, kissing can be difficult and unpleasant due to dry mouth [96]. These problems could lead to a relevant impairment of sexual function in women with SS [96].

The female dominance and the late onset (40 to 50 - years of age) in SS can be explained by the regulatory role of sex hormones [97]. Estrogens seem to protect secretory glandular acinar cells against apoptosis while the lack of estrogens during menopause specifically leads to increased apoptosis of the exocrine cells. Conversely, the male hormone (testosterone) is converted in exocrine glands to dihydrotestosterone (DHT), which is antiapoptotic and protects against acinar cell apoptosis. Estrogen-deficient women need to produce dehydroepiandrosterone (DHEA) in the adrenal glands and convert it to DHT in the exocrine glands through complex enzymatic mechanisms. In SS, such machinery is deranged so that hormonal changes, in part systemic endocrine but predominantly local intracrine, contribute to abnormal apoptosis of secretory acinar cells. The clearance of this overload of apoptotic material may lead to the breakdown of autotolerance in immunogenetically predisposed individuals, giving rise to the complex pathogenic mechanisms of SS.

#### **The therapeutic challenge: old and new treatments**

The therapeutic management of pSS is based on symptomatic treatment of glandular manifestations and on the use of disease-modifying drugs for systemic involvement [98]. Symptomatic treatment with saliva substitutes and eye drops is effective in the relief of sicca syndrome complaints, whereas immunomodulatory and immunosuppressive agents are used in patients with severe extraglandular manifestations and should be tailored to the specific organ involved. The aim of disease-modifying drugs is to restore the deregulated immunological pathways that are accountable for the disease process.

#### **Symptomatic treatment**

Symptomatic treatment not only has beneficial effects on oral and ocular dryness, but can also prevent complications of sicca syndrome. In fact, untreated severe dry eye can result in corneal ulceration, vascularization, opacification and perforation, whereas dry mouth can be complicated by dental caries, oral candidiasis, and periodontal disease.

### Dry mouth topical treatment

Dry mouth topical treatment encompasses the following approaches: (a) non-pharmacological measures including adequate hydration, avoidance of irritants (coffee, alcohol, nicotine, and so on), substitution or reduction of xerostomizing drugs, meticulous oral hygiene (fluoride application, frequent dental examinations, prompt treatment of candidal infections), and sugar-free gums, lozenges and maltose lozenges to increase salivary flow; (b) saliva substitutes (mucin, carboxymethylcellulose, hydroxymethylcellulose) available in the following forms: lubricating gels, mouthwashes, lozenges, toothpastes, intraoral long-release inserts and mucin spray.

A recent Cochrane review of 36 randomized controlled trials (RCTs), involving 1,597 subjects, analyzed the effect of different saliva stimulants and substitutes including lozenges, sprays, mouth rinses, gels, oils, chewing gum or toothpastes, and concluded that there is no strong evidence that any topical therapy is effective for relieving the symptoms of dry mouth [99].

The effect of saliva substitutes on patients with SS was evaluated in four RCTs, enrolling a low number of patients and using a short-term follow-up [98]. Three out of four RCTs showed an effectiveness of saliva substitutes in relieving dry symptoms, but they did not observe any increase in salivary flow.

### Dry eye topical treatment

Dry eye topical treatment approach is based on [100]: (a) non-pharmacologic measures, including avoidance of dry, smoky, windy environments, prolonged reading, computer use, use of humidifiers, goggles with side seals/moisture chambers, avoidance of aggravating drugs (diuretics, beta blockers, tricyclic antidepressants, anti-histamines), and punctal occlusion in refractory cases (plugs, cauterization, surgery); (b) replacement of tear volume, that is, artificial tears (preservative-free products, hypotonic solutions, and emulsions), autologous serum eye drops and platelet releasate, which are promising treatments especially for patients intolerant to artificial tears or with refractory KCS (the major limitation to a widespread use of these products is related to their preparation and preservation); (c) topical drugs counting ciclosporin A, which was approved for the treatment of dry eye by the US Food and Drug administration (FDA) but not by the European Medicine Agency (EMA), corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs).

There are few rigorous studies on the effect of topical medications for eyes in patients with SS. As far as artificial teardrops are concerned, emulsions containing hyaluronate and hydroxypropylmethyl-cellulose, hypotonic solutions that decrease the tear film osmolality, and preservative-free products that are less irritating when

applied chronically on a daily basis, seem to be the best options [98].

In patients with severe KCS, topical NSAIDs can be effective in relieving ocular pain, but they should only be used for a short time and under medical supervision since they reduce corneal sensitivity, predisposing users to corneal damage.

Patients with severe dryness and refractory KCS may also require topical corticosteroid treatment. Although glucocorticoids exert a rapid and intense anti-inflammatory effect, they should only be used for a short time since they can induce severe side effects such as glaucoma and cataracts.

A number of studies were carried out with the use of topical ciclosporin A in patients with KCS and SS, showing good results in terms of dry symptom relief and tear production.

### Systemic drugs for sicca symptoms

Secretagogues are indicated in patients with moderate or severe SS who have dryness and residual exocrinal gland function [100]. Muscarinic receptor agonists, that is, pilocarpine and cevimeline, have been used for both dry mouth and dry eye and data from RCTs demonstrated a substantial benefit on sicca symptoms, and improvements in salivary flow rate and ocular tests results. Cevimeline was approved for the treatment of dry mouth and dry eye by the FDA but not by the EMA. The most frequent side effects of muscarinic receptor agonist therapy are sweating, increased urinary frequency, and flushing. Mucolytic agents, that is bromhexine or *N*-acetylcysteine, have been used for dry mouth although evidence of their efficacy is lacking.

### Disease-modifying drugs

All the drugs currently used in the treatment of autoimmune rheumatic diseases have also been administered to patients with pSS in order to improve sicca symptoms and modify the immune inflammatory pathways involved in disease progression [98]. Unfortunately, evidence supporting the use of these agents is limited.

### Corticosteroids

There are too few studies on oral corticosteroid treatment in patients with SS to draw definitive conclusions. Corticosteroids at high dosage downregulate the immune inflammatory process within the salivary and lacrimal glands [101], but there is no evidence that they increase salivary and lacrimal flow rates. In addition, the chronic use of corticosteroids at high dosage should be avoided in order to prevent severe side effects. Thus, corticosteroids are currently used primarily in patients with extraglandular manifestations or in cases with parotid swelling.

### Antimalarials

Antimalarial agents have been shown to improve sicca features and constitutional symptoms such as fatigue and arthromyalgia [102,103]. Moreover, hydroxychloroquine has been reported to increase salivary flow rate by inhibiting glandular cholinesterase [104], decrease inflammatory indices, that is, ESR and C reactive protein (CRP), and immunological abnormalities, that is,  $\gamma$ -globulin, IgG, IgM, RF, anti-Ro, anti-La. Notably, a decrease of B cell activating factor (BAFF) in the tear fluid of patients using hydroxychloroquine has recently been reported [103].

Importantly, hydroxychloroquine has recently been shown to exhibit antineoplastic properties. In fact, it seems to prevent mutations in cells with high mitotic rate as well as to increase cellular mechanisms of DNA protection and repair [105]. This is an interesting finding since patients with pSS have a significantly higher risk of developing lymphoma than the general population.

### Immunosuppressants

Immunosuppressant agents as ciclosporin A, azathioprine, methotrexate, mycophenolic acid and leflunomide are all used empirically in SS. Indeed, only a few studies including a low number of patients and using a short-term follow-up (6 months) have been published; therefore, their conclusions have a low level of evidence. A benefit on sicca symptoms without significant improvement in objective tests has been reported by some of them. These drugs are currently used in the treatment of extraglandular manifestations and tailored to the organ specific involvement [106].

### Biological drugs

No biologic drugs are currently approved for pSS. However, some published studies have analyzed the off-label therapeutic potential of the following biological agents in pSS: tumor necrosis factor (TNF) $\alpha$  antagonists (etanercept and infliximab), anti-CD20 and anti-CD22 monoclonal antibodies (mAbs).

After three open-label studies in which anti-TNF $\alpha$  agents were shown to improve glandular and extraglandular manifestations, two RCTs failed to demonstrate the superiority of infliximab and etanercept over placebo [107]. Since then, no further studies with the use of these agents have been carried out. Notably, increased type I interferon (IFN)-pathway activation and elevated BAFF serum levels in patients with SS treated with etanercept have been shown [108]. Since type I IFN and BAFF seem to be involved in the pathogenesis of SS as well as of other autoimmune diseases [42], anti-TNF $\alpha$  agents should be avoided in patients with autoimmune diseases, including SS.

A number of uncontrolled studies and two RCTs have been published on anti-CD20 treatment (rituximab) in patients with SS (Table 2) [109-120]. In uncontrolled

studies, rituximab was found to be effective in controlling extraglandular manifestations of the disease including arthritis, skin vasculitis, particularly when associated with cryoglobulins, fatigue, and quality of life; however, only a modest effect on sicca features was demonstrated [121].

In a recently published RCT, 20 patients affected with active primary SS and residual salivary gland function were treated with rituximab and compared to 10 patients on placebo [119]. In comparison with baseline values, rituximab treatment significantly improved the stimulated whole saliva flow rate and several other variables including B cell number, RF levels, unstimulated whole saliva flow rate, lacrimal gland function, fatigue, quality of life, and sicca symptoms. Interestingly, the drug effect lasted 24 weeks and stimulated whole saliva flow rate declined when CD20+ B cells started to repopulate. Despite these promising results, it has been recently shown that rituximab treatment does not alter the characteristic features of increased clonal expansions seen in the parotid salivary glands of patients with pSS [122]. The presence of clonally related immunoglobulin producing cells before and after rituximab treatment strongly suggests that immunoglobulin-producing cells persist in the salivary glands of patients with pSS despite B cell depletion, which can account for disease relapse after treatment [122].

Anti-CD22 mAb (4 infusions of 360 mg/m<sup>2</sup> of epratuzumab once every 2 weeks) was administered to 16 patients with SS in an open-label, phase I/II study, with 6 months of follow-up [123]. A substantial number of patients achieved a significant clinical response based on a composite endpoint and the drug was well tolerated. Epratuzumab acts through a downregulation of CD22, which is overexpressed in the peripheral B cells of patients with SS. According to these preliminary findings, epratuzumab seems to be a promising treatment in patients with SS.

### Conclusions

SS is rather far from being considered a simple disease of 'dry mouth and dry eyes'. Research on SS is extremely active and aims at improving the classification of patients through more objective criteria (for example, the 2012 SICCA Criteria), probing deeper into the etiology and the complex pathogenesis of the disease and providing evidence for the use of new targeted treatments, such as anti-B cell drugs. The role of infections in the emergence of SS has been recently addressed, showing that some infectious agents may promote the disease, while others may have a protective action against the development of autoimmunity. Extraglandular manifestations are still a challenge in the management of SS, among which the most serious is B cell NH lymphoma.

**Table 2 Studies including patients affected with Sjögren's syndrome (SS) treated with rituximab**

Author, year and reference	No. of patients	Study design	Involvement	Efficacy	Safety
Somer <i>et al.</i> , 2003 [109]	1	Case report	Marginal zone lymphoma, xerophthalmia, xerostomia	Improvement in corneal staining, Schirmer's test, salivary flow rate, tear production, salivary pooling, diminished parotid enlargement	No AE reported
Voulgarelis <i>et al.</i> , 2004 [110]	4	Case reports	Marginal zone lymphoma, parotid gland enlargement, lymphadenopathy, cryoglobulinemia, purpura, peripheral neuropathy, arthralgia	Improvement in lymphoma, arthralgia, cryoglobulinemia, purpura, peripheral neuropathy (50%)	No AE reported
Gottenberg <i>et al.</i> , 2005 [111]	6	Retrospective	2 MALT lymphomas, 2 vasculitis with cryoglobulinemia, 2 parotid gland enlargement and articular involvement	Improvement in parotid swelling, subjective dryness, fatigue and vasculitis in 5 out of 6 patients	1 serum sickness, 1 infusion reaction
Pijpe <i>et al.</i> , 2005 [112]	15	Open label	8 early primary SS and 7 MALT lymphoma: 8 parotid gland swelling, 8 Raynaud's phenomenon, 13 fatigue, 11 arthralgia, 2 pulmonary involvement, 2 vasculitis	Remission of lymphoma in 3 of 7 patients, disease stability in 3 of 7, progression in 1. Increased salivary secretion, improvement in the rose Bengal score and tear, BUT, mouth dryness, arthralgia. No improvement on Schirmer test.	2 infusion reactions, 1 Herpes zoster
Ring <i>et al.</i> , 2006 [113]	1	Case report	Distal renal tubular acidosis, xerostomia with mouth ulcerations	Xerostomia improvement	No AE reported
Seror <i>et al.</i> , 2007 [114]	16	Retrospective	5 lymphoma, 2 pulmonary involvement, 2 polysynovitis, 5 mixed cryoglobulinemia, 1 thrombocytopenia, and 1 mononeuritis multiplex	Remission of lymphoma in 4 of 5 patients; improvement of systemic involvements in 9 of 11, subjective dryness in 5 of 16, and regression of keratitis in 2 of 11. No response on salivary flow and Schirmer test.	2 infusion reactions, 1 serum sickness
Devauchelle-Pensec <i>et al.</i> , 2007 [115]	16	Open label	Sicca symptoms, pain, fatigue; 1 pulmonary involvement	Improvement in subjective fatigue, pain, dryness, and pulmonary involvement. No changes in unstimulated salivary flow, salivary gland score and ophthalmologist evaluation.	3 infusion reactions, 1 serum sickness
Dass <i>et al.</i> , 2008 [116]	8 (PL 9)	RCT	Fatigue, ocular and mouth dryness; no systemic involvement	Improvement in fatigue, general health and SF-36. No improvement on Schirmer test and salivary flow rate.	2 infusion reactions, 1 delayed reaction with meningism, 1 gastroenteritis and palpitation
Galarza <i>et al.</i> , 2008 [117]	8	Open label	Severe glandular and musculoskeletal involvement, cutaneous vasculitis	Improvement in parotid swelling, articular involvement, fatigue, and subjective dryness in 4 of 7 patients	3 AE: 2 infusion reactions
Ramos-Casals <i>et al.</i> , 2010 [118]	15	Registry	6 lymphoma, 4 neurological involvement, 2 hematological involvement, 1 refractory glomerulonephritis, arthritis, and protein-losing enteropathy	Complete response in 67% of patients, partial response in 20%, no response in 13%	1 urinary tract infection, 1 interstitial pneumonitis
Meijer <i>et al.</i> , 2010 [119]	20 (PL 10)	RCT	15 arthralgia, 6 arthritis, 2 renal involvement, 1 peripheral neuropathy, 11 Raynaud's phenomenon, 17 tendomyalgia, 6 vasculitis, thyroid dysfunction	Improvement in saliva flow rate, stimulated lacrimal gland function; but not in BUT and Schirmer test. Improvement in SF-36 and MFI. Improvement in extraglandular manifestations.	1 serum sickness, 12 infections in 11 patients on rituximab vs 7 infections in 4 patients on placebo
Mekinian <i>et al.</i> , 2012 [120]	17	Registry	All peripheral nervous system involvement: 10 patients with cryoglobulinemia and/or vasculitis, 7 patients without cryoglobulinemia and/or vasculitis	Response in 9 of 10 patients with cryoglobulinemia and/or vasculitis, and in 2 of 7 without cryoglobulinemia and/or vasculitis	6 (35%) AE: 2 mild arterial hypertension, 1 infusion reaction, 1 cutaneous infection, 1 CMV infection, hypogammaglobulinemia

AE, adverse event; BUT, break-up time; CMV, cytomegalovirus; MALT, mucosa-associated lymphoid tissue; MFI, multidimensional fatigue inventory; PL, placebo; RCT, randomized controlled trial; SF-36, Short Form 36 Health Survey.

The recent finding that severe complications such as lymphoma and peripheral neuropathy are associated with low vitamin D levels opens new avenues in the understanding of the disease and in its treatment. The fact that CHB is also more frequent during winter and associates with hypovitaminosis D supports the idea that the role of vitamin D should be further investigated in SS and adequate supplementation should be given to these patients.

#### Abbreviations

ACA: Anti-centromere antibodies; AECG: American-European Consensus Group; AID: Autoimmune diseases; ANA: Anti-nuclear antibodies; Anti-La: Anti-La/SS-B antibodies; Anti-Ro: Anti-Ro/SS-A antibodies; APS: Antiphospholipid syndrome; BAFF: B cell activating factor; CHB: Congenital heart block; CMV: Cytomegalovirus; CRP: C-reactive protein; DEWS: Dry Eye Workshop; DHT: Dihydrotestosterone; EBV: Epstein-Barr virus; EMA: European Medicine Agency; ESR: Erythrocyte sedimentation rate; FDA: Food and Drug Administration; GMN: Glomerulonephritis; IFN: Interferon; ILD: Interstitial lung disease; IN: Interstitial nephritis; KCS: Keratoconjunctivitis sicca; LFU: Lacrimal functional unit; LIP: Lymphocytic interstitial pneumonia; MALT: Mucosa-associated lymphoid tissue; MCTD: Mixed connective tissue disease; NH: Non-Hodgkin's; NSAIDs: Non-steroidal anti-inflammatory drugs; NSIP: Non-specific interstitial pneumonia; PNS: Peripheral nervous system; RCT: Randomized controlled trial; RF: Rheumatoid factor; SICCA: Sjögren's International Collaborative Clinical Alliance; SS: Sjögren's syndrome; SSc: Systemic sclerosis; pSS: Primary Sjögren's syndrome; sSS: Secondary Sjögren's syndrome; UIP: Usual interstitial pneumonia; US: Ultrasound; VDR: Vitamin D receptor.

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

All authors were involved in drafting the manuscript and approved the final version.

#### Acknowledgements

We thank Dr Mirko Scarsi (Rheumatology and Clinical Immunology Unit, Brescia, Italy) for the concept and production of the figure on the cover page, and to Dr Barbara Arcidiacono (Ophthalmology Unit, Brescia) for support in the preparation of the 'dry eye' section. LA is supported by a Research Grant financed by an agreement between the Government of Lombardy and the University of Brescia ('Dote Ricercatore e Dote Ricerca Applicata ai sensi dell'accordo regionale per lo sviluppo del capitale umano nel sistema universitario Lombardo sottoscritto tra Regione Lombardia e Università Lombarde il 20-10-2009, Università degli Studi di Brescia').

#### Author details

<sup>1</sup>Rheumatology and Clinical Immunology Unit, Spedali Civili, Piazzale Spedali Civili 1, 25100 Brescia, Italy. <sup>2</sup>Chair of Rheumatology, Department of Clinical and Experimental Sciences, University of Brescia, Spedali Civili, Piazzale Spedali Civili 1, 25100 Brescia, Italy. <sup>3</sup>Rheumatology Unit, Department of Medicine, University of Padua, Azienda Ospedaliera di Padova, Via Giustiniani 2, 35128 Padua, Italy. <sup>4</sup>Rheumatology Unit, Vallecannonica Hospital, Via Manzoni 142, 25040 Esine (Brescia), Italy. <sup>5</sup>Obstetrics and Gynecology Unit, Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, 25100 Brescia, Italy. <sup>6</sup>Ophthalmology Unit, Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, 25100 Brescia, Italy. <sup>7</sup>Pathology Unit, Spedali Civili, Piazzale Spedali Civili 1, 25100 Brescia, Italy. <sup>8</sup>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Hashomer 52621, Israel.

Received: 19 November 2012 Accepted: 15 February 2013

Published: 4 April 2013

#### References

1. Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y: **Sjögren's syndrome, the old and the new.** *Best Pract Res Clin Rheumatol* 2012, **26**:105–117.

- Mavragani CP, Moutsopoulos HM: **The geoepidemiology of Sjögren's syndrome.** *Autoimmun Rev* 2010, **9**:A305–A310.
- Ice JA, Li H, Adrianto I, Lin PC, Kelly JA, Montgomery CG, Lessard CJ, Moser KL: **Genetics of Sjögren's syndrome in the genome-wide association era.** *J Autoimmun* 2012, **39**:57–63.
- Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM: **HLA and Sjögren's syndrome susceptibility. A meta-analysis of worldwide studies.** *Autoimmun Rev* 2012, **11**:281–287.
- Roitberg-Tambur A, Friedmann A, Safirman C, Markitziu A, Ben-Chetrit E, Rubinow A, Moutsopoulos HM, Stavropoulos E, Skopouli FN, Margalit H: **Molecular analysis of HLA class II genes in primary Sjögren's syndrome. A study of Israeli Jewish and Greek non-Jewish patients.** *Hum Immunol* 1993, **36**:235–242.
- Piram M, Maldinia C, Mahr A: **Effect on race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides.** *Curr Opin Rheum* 2012, **24**:193–200.
- Ramos-Casals M, Brito-Zerón P, Sisò-Almirall A, Bosch X: **Primary Sjögren syndrome.** *BMJ* 2012, **344**:e3821.
- Tzioufas AG, Moutsopoulos HM: **Sjögren's syndrome.** In *Rheumatology*. 2nd edition. Edited by Klippel JH, Dieppe PA. Maryland Heights, MI: Mosby; 1999, 7.32.1-11.
- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassar SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren's syndrome: **Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.** *Ann Rheum Dis* 2002, **61**:554–558.
- Baldini C, Talarico R, Tzioufas AG, Bombardieri S: **Classification criteria for Sjögren's syndrome: a critical review.** *J Autoimmun* 2012, **39**:9–14.
- Guellec D, Cornec D, Jousse-Joulin S, Marhadour T, Marcocelles P, Pers JO, Saraux A, Devauchelle-Pensec V: **Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: a systematic review.** *Autoimmun Rev* 2013, **12**:416–420.
- Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan J, Daniels T: **American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.** *Arthritis Care Res (Hoboken)* 2012, **64**:475–487.
- Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, Hamann S, Larkin G, McNamara NA, Greenspan JS, Daniels TE: **Sjögren's International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry.** *Am J Ophthalmol* 2010, **149**:405–415.
- Tzioufas AG, Moutsopoulos HM: **Ultrasonography of salivary glands: an evolving approach for the diagnosis of Sjögren's syndrome.** *Nat Clin Pract Rheumatol* 2008, **4**:454–455.
- Salaffi F, Carotti M, Iagnocco A, Luccioli F, Ramonda R, Sabatini E, De Nicola M, Maggi M, Priori R, Valesini G, Gerli R, Punzi L, Giuseppetti GM, Salvolini U, Grassi W: **Ultrasonography of salivary glands in primary Sjögren's syndrome: a comparison with contrast sialography and scintigraphy.** *Rheumatology (Oxford)* 2008, **47**:1244–1249.
- Milic V, Petrovic R, Boricic I, Radunovic G, Marinkovic-Eric J, Jeremic P, Damjanov N: **Ultrasonography of major salivary glands could be an alternative tool to sialoscintigraphy in the American-European classification criteria for primary Sjögren's syndrome.** *Rheumatology* 2012, **51**:1081–1085.
- Thoft RA, Friend J: **The X, Y, Z hypothesis of corneal epithelial maintenance.** *Invest Ophthalmol Vis Sci* 1983, **24**:1442.
- Lemp MA: **Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes.** *CLAO J* 1995, **21**:221–232.
- Dry Eye Workshop: **The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop.** *Ocul Surf* 2007, **5**:75–92.
- Stern ME, Pflugfelder SC: **Inflammation in dry eye.** *Ocul Surf* 2004, **2**:124–130.
- García-Carrasco M, Ramos-Casals R, Rosas J, Pallares L, Calvo-Alen J, Cervera R, Font J, Ingelmo M: **Primary Sjögren's syndrome. Clinical and**

- immunological disease patterns in a cohort of 400 patients. *Medicine* 2002, **81**:270–280.
22. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM: **Clinical evolution and morbidity and mortality of primary Sjögren's syndrome.** *Seminars Arthritis Rheum* 2000, **29**:296–304.
  23. ter Borg EJ, Risselada AP, Kelder JC: **Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjögren's syndrome: a retrospective analysis of 65 patients in the Netherlands.** *Seminars Arthritis Rheum* 2011, **40**:547–551.
  24. Seror R, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Ramos-Casals M, Ravaud P, Theander E, Tzioufas A, Vitali C: **Outcome measures for primary Sjögren's syndrome.** *J Autoimmun* 2012, **39**:97–102.
  25. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, Calvo-Alen J, Jimenez-Alonso J, Mico ML, Beltran J, Belenguer R, Pallares L, and the GEMESS Study Group: **Primary Sjögren's syndrome in Spain. Clinical and immunological expression in 1010 patients.** *Medicine* 2008, **87**:210–219.
  26. Manoussakis MN, Kapsogeorgou EK: **The role of intrinsic epithelial activation in the pathogenesis of Sjögren's syndrome.** *J Autoimmun* 2010, **35**:219–224.
  27. Selmi C, Meroni PL, Gershwin ME: **Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis.** *J Autoimmun* 2012, **39**:34–42.
  28. Ng WF, Bowman SJ: **Primary Sjögren's syndrome: too dry and too tired.** *Rheumatology* 2012, **49**:844–853.
  29. Hatron PY, Tillie-Leblond I, Launay D, Hachulla E, Fauchais AL, Wallaert B: **Pulmonary manifestations of Sjögren's syndrome.** *Presse Med* 2011, **40**:e49–e64.
  30. Bossini N, Savoldi S, Franceschini F, Mombelloni S, Baronio M, Cavazzana I, Viola BF, Valzorio B, Mazzucchelli C, Cattaneo R, Scolari F, Maiorca R: **Clinical and morphological features of kidney involvement in primary Sjögren's syndrome.** *Nephrol Dial Transplant* 2001, **16**:2328–2336.
  31. Kittridge A, Routhouska SB, Korman NJ: **Dermatologic manifestations of Sjögren syndrome.** *J Cutan Med Surg* 2011, **15**:8–14.
  32. Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, Lambert M, Launay D, Loustaud-Ratti V, Bezanahari H, Liozon E, Hachulla E, Jouberteau MO, Vidal E, Hatron PY: **Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients.** *Rheumatology (Oxford)* 2010, **49**:1164–1172.
  33. Ebert EC: **Gastrointestinal and hepatic manifestations of Sjögren syndrome.** *J Clin Gastroenterol* 2012, **46**:25–30.
  34. Mavragani CP, Fragoulis GE, Moutsopoulos HM: **Endocrine alterations in primary Sjögren's syndrome: an overview.** *J Autoimmun* 2012, **39**:354–358.
  35. Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, Dalakas MC: **Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms.** *J Autoimmun* 2012, **39**:27–33.
  36. Chai J, Logigian EL: **Neurological manifestations of primary Sjögren's syndrome.** *Curr Opin Neurol* 2010, **23**:509–513.
  37. Singh N, Cohen PL: **The T cell in Sjögren's syndrome: force majeure, not spectateur.** *J Autoimmun* 2012, **39**:229–233.
  38. Corneer D, Devauchelle-Pensec V, Tobón GJ, Pers JO, Jousse-Joulin S, Saraux A: **B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.** *J Autoimmun* 2012, **39**:161–167.
  39. Varin MM, Guerrier T, Devauchelle-Pensec V, Jamin C, Youinou P, Pers JO: **In Sjögren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation.** *Autoimmun Rev* 2012, **11**:252–258.
  40. Manoussakis MN, Boiu S, Korkolopoulou P, Kapsogeorgou EK, Kavantzias N, Ziakas P, Patsouris E, Moutsopoulos HM: **Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development.** *Arthritis Rheum* 2007, **56**:3977–3988.
  41. González S, Aguilera S, Urzúa U, Quest AF, Molina C, Alliende C, Hermoso M, González MJ: **Mechanotransduction and epigenetic control in autoimmune diseases.** *Autoimmun Rev* 2011, **10**:175–179.
  42. Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM: **Pathogenesis of Sjögren's syndrome: what we know and what we should learn.** *J Autoimmun* 2012, **39**:4–8.
  43. Regezi JA, Scuibba JJ, Jordan RCK: *Oral Pathology - Clinical pathological Correlations.* 6th edition. New York, NY: Elsevier-Saunders; 2012.
  44. Tzioufas AG, Voulgarelis M: **Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias.** *Best Pract Res Clin Rheumatol* 2007, **21**:989–1010.
  45. Zandbelt MM, Vogelzangs J, Van De Putte LB, Van Venrooij WJ, Van Den Hoogen FH: **Anti-alpha-fodrin antibodies do not add much to the diagnosis of Sjögren's syndrome.** *Arthritis Res Ther* 2004, **6**:R33–R38.
  46. Bournia VK, Vlachoyiannopoulos PG: **Subgroups of Sjögren syndrome patients according to serological profiles.** *J Autoimmun* 2012, **39**:15–26.
  47. Hernández-Molina G, Leal-Alegre G, Michel-Peregrina M: **The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome.** *Autoimmun Rev* 2011, **10**:123–125.
  48. Barcellos KS, Nonogaki S, Enokihara MM, Teixeira MS, Andrade LE: **Differential expression of Ro/SSA 60 kDa and La/SSB, but not Ro/SSA 52 kDa, mRNA and protein in minor salivary glands from patients with primary Sjögren's syndrome.** *J Rheumatol* 2007, **34**:1283–1292.
  49. Sisto M, Lisi S, Lofrumento D, D'Amore M, Scaglioni P, Mitolo V: **Autoantibodies from Sjögren's syndrome trigger apoptosis in salivary gland cell line.** *Ann N Y Acad Sci* 2007, **1108**:418–425.
  50. Lisi S, Sisto M, Lofrumento DD, Cucci L, Frassanito MA, Mitolo V, D'Amore M: **Pro-inflammatory role of Anti-Ro/SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis.** *J Autoimmun* 2010, **35**:160–170.
  51. Defendenti C, Atzeni F, Spina MF, Grosso SA, Alyanakian MA, Chretien P, Saibeni S, Puttini PS: **Clinical and laboratory aspects of Ro/SSA-52 autoantibodies.** *Autoimmun Rev* 2011, **10**:150–154.
  52. Ghillani P, André C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Gouvestre C, Gleizes A, Dragon-Durey M, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C: **Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study.** *Autoimmun Rev* 2011, **10**:509–513.
  53. Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F: **Autoantibodies to intracellular antigens: generation and pathogenetic role.** *Autoimmun Rev* 2011, **10**:503–508.
  54. Franceschini F, Cavazzana I: **Anti-Ro/SSA and La/SSB antibodies.** *Autoimmunity* 2005, **38**:55–63.
  55. Ramos-Casals M, Nardi N, Brito-Zerón P, Aguiló S, Gil V, Delgado G, Bové A, Font J: **Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases.** *Semin Arthritis Rheum* 2006, **35**:312–321.
  56. Cavazzana I, Franceschini F, Vassalini C, Danieli E, Quinzanini M, Airo P, Cattaneo R: **Clinical and serological features of 35 patients with anti-Ki autoantibodies.** *Lupus* 2005, **14**:837–841.
  57. Onouchi H, Muro Y, Tomita Y: **Clinical features and IgG subclass distribution of anti-p80 coilin antibodies.** *J Autoimmun* 1999, **13**:225–232.
  58. Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airo P, Cattaneo R, Franceschini F: **Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases.** *Lupus* 2008, **17**:727–732.
  59. Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, Ghirardello A, Punzi L, Doria A: **Overlap connective tissue disease syndromes.** *Autoimmun Rev* 2013, **12**:363–373.
  60. Lazarus MN, Isenberg DA: **Development of additional autoimmune diseases in a population of patients with primary Sjögren's syndrome.** *Ann Rheum Dis* 2005, **64**:1062–1064.
  61. Amador-Patarroyo MJ, Arbelaez JG, Mantilla RD, Rodriguez-Rodriguez A, Cárdenas-Roldán J, Pineda-Tamayo R, Guarín MR, Kleine LL, Rojas-Villarraga A, Anaya JM: **Sjögren's syndrome at the crossroad of polyautoimmunity.** *J Autoimmun* 2012, **39**:199–205.
  62. Yao Q, Altman RD, Wang X: **Systemic lupus erythematosus with Sjögren syndrome compared to systemic lupus erythematosus alone: a meta-analysis.** *J Clin Rheumatol* 2012, **18**:28–32.
  63. Theander E, Jacobsson LTH: **Features of systemic lupus erythematosus in patients with primary Sjögren's syndrome. A cross-sectional analysis of the 11 items of the SLE criteria set and the levels of complement factors C3 and C4 in 100 primary Sjögren's syndrome patients.** *Lupus* 2005, **14**:S231.
  64. Fauchais AL, Martel C, Gondran G, Lambert M, Launay D, Jouberteau MO, Hachulla E, Vidal E, Hatron PY: **Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease.** *Autoimmun Rev* 2010, **9**:595–599.
  65. Carmona L, González-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmartí R: **Rheumatoid arthritis in Spain: occurrence of extra-articular**



- manifestations and estimates of disease severity. *Ann Rheum Dis* 2003, **62**:897–900.
66. Skoumal M, Wottawa A: Long-term observation study of Austrian patients with rheumatoid arthritis. *Acta Med Austriaca* 2002, **29**:52–56.
67. Alexiou I, Germeis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI: Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. *Clin Rheumatol* 2008, **27**:511–513.
68. Kauppi M, Pukkala E, Isomaki H: Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). *Cancer Causes Control* 1997, **8**:201–204.
69. Rodnan G: The natural history of progressive sclerosis (diffuse scleroderma). *Bull Rheum Dis* 1963, **1963**:203–205.
70. Alarcón-Segovia D, Ibáñez G, Hernández-Ortiz J, Velázquez-Forero F, González-Jiménez Y: Sjögren's syndrome in progressive systemic sclerosis (scleroderma). *Am J Med* 1974, **57**:78–85.
71. Avouac J, Sordet C, Depinay C, Ardizzone M, Vacher-Lavenu MC, Sibilia J, Kahan A, Allanore Y: Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. *Arthritis Rheum* 2006, **54**:2243–2249.
72. Salliot C, Gottenberg JE, Bengoufa D, Desmoulin F, Miceli-Richard C, Mariette X: Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome. *J Rheumatol* 2007, **34**:2253–2258.
73. Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Bizzaro N, Gilburd B, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Mackay IR, Orbach H, Ram M, Sherer Y, Toubi E, Gershwin ME: The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases—2008. *Isr Med Assoc J* 2008, **10**:13–19.
74. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y: Autoimmunity and environment: infections and autoimmunity - friends or foes? *Trends Immunol* 2009, **30**:409–414.
75. Shapira Y, Agmon-Levin N, Selmi C, Petriková J, Barzilai O, Ram M, Bizzaro N, Valentini G, Matucci-Cerinic M, Anaya JM, Katz BS, Shoenfeld Y: Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. *J Autoimmun* 2012, **39**:112–116.
76. Sagi L, Baum S, Agmon-Levin N, Sherer Y, Katz BS, Barzilai O, Ram M, Bizzaro N, Sanmarco M, Trau H, Shoenfeld Y: Autoimmune bullous diseases. The spectrum of infectious agent antibodies and review of the literature. *Autoimmun Rev* 2011, **10**:527–535.
77. Agmon-Levin N, Shapira Y, Selmi C, Barzilai O, Ram M, Szyper-Kravitz M, Sella S, Katz BS, Youinou P, Renaudineau Y, Larida B, Invernizzi P, Gershwin ME, Shoenfeld Y: A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. *J Autoimmun* 2010, **34**:55–58.
78. Zinger H, Sherer Y, Goddard G, Berkun Y, Barzilai O, Agmon-Levin N, Ram M, Blank M, Tincani A, Rozman B, Cervera R, Shoenfeld Y: Common infectious agents prevalence in antiphospholipid syndrome. *Lupus* 2009, **18**:1149–1153.
79. Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, Sherer Y, Anaya JM, Shoenfeld Y: Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. *Ann NY Acad Sci* 2009, **1173**:658–663.
80. Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz B, Bizzaro N, Tonutti E, Maieron R, Chowers Y, Bar-Meir S, Shoenfeld Y: Infectious serologies and autoantibodies in inflammatory bowel diseases. Insinuations at a true pathogenic role. *Ann NY Acad Sci* 2009, **1173**:640–648.
81. Agmon-Levin N, Kivity S, Tzioufas AG, López Hoyos M, Rozman B, Efes I, Shapira Y, Shamis A, Amital H, Youinou P, Shoenfeld Y: Low levels of vitamin D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome. *J Autoimmun* 2012, **39**:234–239.
82. Kiraly SJ, Kiraly MA, Hawe RD, Makhani N: Vitamin D as a neuroactive substance: review. *Scientific World J* 2006, **6**:125–139.
83. Chabas JF, Alluin O, Rao G, Garcia S, Lavaut MN, Risso JJ, Legre R, Magalon G, Khrestchatsky M, Marquette T, Decherchi P, Feron F: Vitamin D2 potentiates axon regeneration. *J Neurotrauma* 2008, **25**:1247–1256.
84. Turner MK, Hooten WM, Schmidt JE, Kerkvliet JL, Townsend CO, Bruce BK: Prevalence and clinical correlates of vitamin D inadequacy among patients with chronic pain. *Pain Med* 2008, **9**:979–984.
85. Skalli S, Muller M, Pradines S, Halimi S, Wion-Barbot N: Vitamin D deficiency and peripheral diabetic neuropathy. *Eur J Intern Med* 2012, **23**:e67–e68.
86. Valensi P, Le Devehat C, Richard JL, Farez C, Khodabandehlou T, Rosenbloom RA, LeFante C: A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. *J Diabetes Complications* 2005, **19**:247–253.
87. Lee P, Chen R: Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. *Arch Intern Med* 2008, **168**:771–772.
88. Polesel J, Talamini R, Montella M, Parpinel M, Dal Maso L, Crispo A, Crovatto M, Spina M, La Vecchia C, Franceschi S: Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. *Ann Oncol* 2006, **17**:713–718.
89. Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG: Vitamin D and non-Hodgkin lymphoma risk in adults: a review. *Cancer Invest* 2009, **27**:942–951.
90. Hickish T, Cunningham D, Colston K, Millar BC, Sandle J, Mackay AG, Soukop M, Sloane J: The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. *Br J Cancer* 1993, **68**:668–672.
91. Andreoli L, Fredi M, Nalli C, Reggia R, Lojaco A, Motta M, Tincani A: Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. *J Autoimmun* 2012, **38**:J197–J208.
92. Ambrosi A, Salomonsson S, Eliasson H, Zeffer E, Skog A, Dzikaite V, Bergman G, Fernlund E, Tingström J, Theander E, Rydberg A, Skogh T, Öhman A, Lundström U, Mellander M, Winqvist O, Fored M, Ekbohm A, Alfreðsson L, Källberg H, Olsson T, Gadler F, Jonzon A, Kockum I, Sonesson SE, Wahren-Herlenius M: Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern. *Ann Rheum Dis* 2012, **71**:334–340.
93. Brucato A, Doria A, Frassi M, Castellino G, Franceschini F, Faden D, Pisoni MP, Solerte L, Muscarà M, Lojaco A, Motta M, Cavazzana I, Ghirardello A, Vescovi F, Tombini V, Cimaz R, Gambari PF, Meroni PL, Canesi B, Tincani A: Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. *Lupus* 2002, **11**:716–721.
94. Marchesoni D, Mozzanega B, De Sandre R, Romagnolo C, Gambari PF, Maggino T: Gynaecological aspects of primary Sjögren's syndrome. *Eur J Obstet Gynecol Reprod Biol* 1995, **63**:49–53.
95. Haga HJ, Gjesdal CG, Irgens LM, Ostensen M: Reproduction and gynaecological manifestations in women with primary Sjögren's syndrome: a case-control study. *Scand J Rheumatol* 2005, **34**:45–48.
96. Tristano AG: The impact of rheumatic diseases on sexual function. *Rheumatol Int* 2009, **29**:853–860.
97. Kontinen YT, Fuellen G, Bing Y, Porola P, Stegaev V, Trokovic N, Falk SS, Liu Y, Szodoray P, Takakubo Y: Sex steroids in Sjögren's syndrome. *J Autoimmun* 2012, **39**:49–56.
98. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG: Topical and systemic medications for the treatment of primary Sjögren's syndrome. *Nat Rev Rheumatol* 2012, **8**:399–411.
99. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R: Interventions for the management of dry mouth: topical therapies. *Cochrane Database Syst Rev* 2011, **7**:CD008934.
100. Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ: Treatment of Sjögren's syndrome-associated dry eye: an evidence-based review. *Ophthalmology* 2011, **118**:1242–1252.
101. Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L, Doria A: The kaleidoscope of glucocorticoid effects on immune system. *Autoimmun Rev* 2011, **10**:305–310.
102. Rihl M, Ulbricht K, Schmidt RE, Witte T: Treatment of sicca symptoms with hydroxychloroquine in patients with Sjögren's syndrome. *Rheumatology (Oxford)* 2009, **48**:796–799.
103. Yavuz S, Asfuroğlu E, Bicakçigil M, Toker E: Hydroxychloroquine improves dry eye symptoms of patients with primary Sjögren's syndrome. *Rheumatol Int* 2011, **31**:1045–1049.
104. Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM: Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. *Rheumatology (Oxford)* 2005, **44**:449–455.
105. Doria A, Arienti S, Rampudda M, Canova M, Tonon M, Sarzi-Puttini P: Preventive strategies in systemic lupus erythematosus. *Autoimmun Rev* 2008, **7**:192–197.
106. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttini P, Doria A: Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? *Autoimmun Rev* 2007, **6**:190–195.
107. Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P: Potential target of infliximab in autoimmune and inflammatory diseases. *Autoimmun Rev* 2007, **6**:529–536.

108. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK: **Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.** *Arthritis Rheum* 2007, **56**:3995–4004.
109. Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ, American College of Rheumatology ad hoc Committee on Immunologic Testing Guidelines: **Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.** *Arthritis Rheum* 2003, **49**:394–398.
110. Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG: **Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.** *Rheumatology (Oxford)* 2004, **43**:1050–1053.
111. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X, Club Rhumatismes et Inflammation (CRI): **Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.** *Ann Rheum Dis* 2005, **64**:913–920.
112. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H: **Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.** *Arthritis Rheum* 2005, **52**:2740–2750.
113. Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B: **Successful treatment of a patient with primary Sjögren's syndrome with rituximab.** *Clin Rheumatol* 2006, **25**:891–894.
114. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X: **Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.** *Ann Rheum Dis* 2007, **66**:351–357.
115. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roué IQ, Cochener B, Youinou P, Saraux A: **Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).** *Arthritis Rheum* 2007, **57**:310–317.
116. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P: **Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.** *Ann Rheum Dis* 2008, **67**:1541–1544.
117. Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Rueda JC, Anaya JM: **Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?** *Clin Rev Allergy Immunol* 2008, **34**:124–128.
118. Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxo A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J, BIOGEAS Study Group: **Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.** *Clin Exp Rheumatol* 2010, **28**:468–476.
119. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H: **Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.** *Arthritis Rheum* 2010, **62**:960–968.
120. Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B, Hamidou M, Cantagrel A, Marcelli C, Rist S, Breban M, Launay D, Fain O, Gottenberg JE, Mariette X: **Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry.** *Ann Rheum Dis* 2012, **71**:84–87.
121. Atzeni F, Doria A, Turiel M, Sarzi-Puttini P: **What is the role of rituximab in the treatment of rheumatoid arthritis?** *Autoimmun Rev* 2007, **6**:553–558.
122. Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA: **Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.** *Ann Rheum Dis* 2012, **71**:1881–1887.
123. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O: **Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.** *Arthritis Res Ther* 2006, **8**:R129.

doi:10.1186/1741-7015-11-93

Cite this article as: Tincani et al.: Novel aspects of Sjögren's syndrome in 2012. *BMC Medicine* 2013 **11**:93.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

